C34.10C34.11C34.12C34.30+5 more

Lung Cancer

Malignant neoplasm of the bronchus or lung, a leading cause of cancer mortality.

Persistent coughHemoptysisDyspneaChest painWeight lossHoarseness

Key Documentation Elements

  • TNM staging
  • Histologic type (NSCLC vs SCLC)
  • Molecular markers (EGFR, ALK, PD-L1, KRAS)
  • Performance status (ECOG)
  • Current treatment regimen
  • Response assessment (RECIST criteria)

Documentation Challenges

  • Documenting TNM staging and histologic type
  • Recording molecular markers and targeted therapy eligibility
  • Capturing performance status for treatment planning
  • Tracking treatment response and progression

Billing Considerations

  • Lobe-specific coding with laterality
  • Active treatment vs surveillance coding
  • Molecular testing documentation for targeted therapy
  • Immunotherapy and chemotherapy administration billing

Frequently Asked Questions

How is lung cancer coded by location?

Lung cancer uses C34.x with lobe specificity: C34.10 (upper lobe), C34.2 (middle lobe), C34.30 (lower lobe), C34.80 (overlapping), C34.90 (unspecified). Laterality is specified. Scribeable codes from documented imaging and pathology.

How does Scribeable support lung cancer documentation?

Scribeable captures staging, histology, molecular markers, performance status, and treatment response from your encounter to generate comprehensive oncology documentation with accurate ICD-10 coding.

Automate Lung Ca Documentation

Scribeable captures all required elements for Lung Ca from your patient conversation. AI-assisted ICD-10 coding and HCC capture.

ICD-10 Codes

C34.10C34.11C34.12C34.30C34.31C34.32C34.90C34.91C34.92

Lung Cancer Documentation Guide

Malignant neoplasm of the bronchus or lung, a leading cause of cancer mortality.

ICD-10 Codes: C34.10, C34.11, C34.12, C34.30, C34.31, C34.32, C34.90, C34.91, C34.92

Common Symptoms

  • Persistent cough
  • Hemoptysis
  • Dyspnea
  • Chest pain
  • Weight loss
  • Hoarseness

Key Documentation Elements

  • TNM staging
  • Histologic type (NSCLC vs SCLC)
  • Molecular markers (EGFR, ALK, PD-L1, KRAS)
  • Performance status (ECOG)
  • Current treatment regimen
  • Response assessment (RECIST criteria)

Documentation Challenges

  • Documenting TNM staging and histologic type
  • Recording molecular markers and targeted therapy eligibility
  • Capturing performance status for treatment planning
  • Tracking treatment response and progression

Billing Considerations

  • Lobe-specific coding with laterality
  • Active treatment vs surveillance coding
  • Molecular testing documentation for targeted therapy
  • Immunotherapy and chemotherapy administration billing

Frequently Asked Questions

How is lung cancer coded by location?

Lung cancer uses C34.x with lobe specificity: C34.10 (upper lobe), C34.2 (middle lobe), C34.30 (lower lobe), C34.80 (overlapping), C34.90 (unspecified). Laterality is specified. Scribeable codes from documented imaging and pathology.

How does Scribeable support lung cancer documentation?

Scribeable captures staging, histology, molecular markers, performance status, and treatment response from your encounter to generate comprehensive oncology documentation with accurate ICD-10 coding.

Related Conditions